Growing evidence shows that lower doses or shorter treatments of precision cancer therapies could reduce toxicity and save money — but more clinical trials are needed.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Szmulewitz, R. Z. et al. J. Clin. Oncol. 36, 1389–1395 (2018).
Iquiva. https://go.nature.com/3uNj5xY (26 May 2022).
Patil, V. M. et al. J. Oncol. 41, 222–232 (2023).
Sonke, G. S. et al. J. Clin. Oncol. 41, LBA1000 (2023).
Earl, H. M. et al. Ann. Oncol. 32, S1283 (2021).
Bayle, A., Besse, B., Annereau, M. & Bonastre, J. Eur. J. Cancer 113, 28–31 (2019).
Malmberg, R. et al. Lancet Oncol. 23, e552–e561 (2022).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moutinho, S. Dozens of precision cancer drugs tested at lower doses to reduce side effects and cut costs. Nat Med 30, 611–614 (2024). https://doi.org/10.1038/s41591-024-02845-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-02845-7
